API | sovaprevir

sovaprevir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Sovaprevir is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor. Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012. ^Wikipedia

Chemistry

SMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](CC(=O)N1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
InChIKey: MHFMTUBUVQZIRE-WINRQGAFSA-N
Mol. Mass: 799.99
ALogP: 4.99 Partition coefficient
ChEMBL Molecule:
sovaprevir

More Chemistry

Pharmacology

Mechanism of Action:
- Genome polyprotein (Hepatitis C virus) ^UniProt
- Non-structural protein 4A (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ach-0141625 | sovaprevir

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue